Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial

Abstract

ObjectiveTo compare the safety and effectiveness of fixed-combination regimes (latanoprost– timolol and brinzolamide 1% compared to dorzolamide 1%/timolol and latanoprost) in open-angle glaucoma patients after switching from a combination of three topical antiglaucoma eye drops.MethodsWe conducted an open, randomized 12-week multicenter prospective study. We randomly allocated 39 patients who had been treated with three antiglaucoma eye drops (prostaglandin F2α analogues plus beta-blockers and carbonic anhydrase inhibitors) into two groups. Group A (n = 20) were treated with latanoprost–timolol and brinzolamide 1% therapy and Group B (n = 16) were treated with dorzolamide 1%/timolol and latanoprost. Thirty-six patients completed all 12 weeks of this study. The major clinical parameters measured were intraocular pressure (IOP), conjunctive hyperemia, superficial punctate keratopathy and hyperpigmentation of eyelid at baseline, 4, and 12 weeks. Additionally noted were adverse events and patient preferences, measured using a questionnaire at study initiation and at 12 weeks.ResultsAt baseline, IOPs were (Group A: 14.1 ± 2.9 mmHg, B: 14.5 ± 2.9 mmHg; P = 0.658), (Group A: 13.8 ± 2.6 mmHg, B: 14.3 ± 2.8 mmHg; P = 0.715) at 4 weeks, and (Group A: 14.1 ± 2.7 mmHg, B: 14.2 ± 2.7 mmHg; P = 0.538) at 12 weeks. Among the groups, there was no significant difference at any time point after baseline (P = 0.923, 0.951, respectively). All adverse events were not remarkably different after therapy. In regards to patient preference before and after switching therapy, 10 patients (50%) in Group A and 10 patients (63%) in Group B preferred using fixed-combination eye drop therapy.ConclusionsEffectiveness and safety were maintained in both groups after switching therapy. Overall, patients generally preferred using a fixed-combination therapy.

Comparison of Latanoprost/Timolol with Carbonic Anhydrase Inhibitor and Dorzolamide/Timolol with Prostaglandin Analog in the Treatment of Glaucoma

“…Adverse reactions associated with the use of the DTFC eye drops include hyperemia, feelings of stimulation, itching, foreign body sensations, conjunctivitis, superficial punctate keratitis, headache, bitter taste, and blurred vision [1, 8–11]. We observed similar adverse reactions in the current study, which included blurred vision, feeling of stimulation, chest pain, and asthma attack.…”

“…Nakakura et al [1] investigated this in patients with primary open-angle glaucoma who were using PG analogs, β -blockers, and CAI concomitantly. In that study, each patient was switched to either LTFC with brinzolamide eye drops (20 cases) or to DTFC with latanoprost eye drops (16 cases).…”

“…Some physicians choose to switch patients from a three-drug regimen to a two-drop regimen by switching PG analogs and β -blockers to prostaglandin/timolol fixed-combination eye drops or from β -blockers and CAIs to DTFC eye drops. Unfortunately, only one previous report has investigated the impacts of such medication changes [ 1 ].…”

Drug‐induced hperpigemntation: a systematic review

“…Eleven case‐control studies were identified; of these, 1 was on amiodarone , 1 on antimalarial drugs , 1 on bimatoprost , 4 on latanoprost −, 1 on phenothiazine , and 3 on smoking −. In addition, 5 randomized, controlled studies (RCT) were identified, of which 2 were on latanoprost and 2 on bimatoprost , comparing different treatment methods, and 1 placebo‐controlled study on minocycline .…”

Systematischer Review zum Zusammenhang Hyperpigmentierungen der Haut und der Einnahme von Medikamenten

“…Tabelle 1 Medikamente, für die ein Zusammenhang mit Hyperpigmentierungen berichtet wurde (Klassifikation nach ATC).Des Weiteren wurden 5 randomisierte, kontrollierte Studien (RCT) gefunden, davon 2 zu Latanoprost[15,16] und 2 zu Bimatoprost[17,18] mit Vergleichen verschiedener Behandlungsmethoden, dazu eine placebokontrollierte Studie zu Minocyclin [19]. Sechsundzwanzig der Berichte stammten aus den Jahren vor 1989, 65 aus dem Zeitraum bis 1999, 173 bis 2009, die restlichen 42 Berichte aus den Jahren 2010 bis 2012.…”